Juvenile Idiopathic Arthritis (JIA) Overview
Learn About Juvenile Idiopathic Arthritis (JIA)
View Main Condition: Arthritis
Adam Huber is a Pediatric Rheumatologist in Halifax, Canada. Mr. Huber is rated as an Elite expert by MediFind in the treatment of Juvenile Idiopathic Arthritis (JIA). His top areas of expertise are Juvenile Dermatomyositis, Dermatomyositis, Juvenile Idiopathic Arthritis (JIA), Arthritis, and Bone Marrow Aspiration.
Hans-iko Huppertz practices in Bremen, Germany. Mr. Huppertz is rated as an Elite expert by MediFind in the treatment of Juvenile Idiopathic Arthritis (JIA). His top areas of expertise are Juvenile Idiopathic Arthritis (JIA), Arthritis, Lyme Disease, and Flu.
Duke Children's Health Center Rheumatology Clinic
I care for children with childhood arthritis, autoimmune, and autoinflammatory conditions. The relationship I build with my patients and families is one of the most rewarding parts of my career. I believe it is that collaborative relationship that is crucial to managing these often chronic conditions that affect children so differently. I also remain committed to providing opportunities for patients and families to become involved in research and advocacy to help to move the field forward and improve the care we offer to children. With our joint commitment, we will be able to advance our knowledge, optimize available treatments, and eventually find a cure for these rare conditions. Dr. Becker is rated as an Elite provider by MediFind in the treatment of Juvenile Idiopathic Arthritis (JIA). Her top areas of expertise are Juvenile Idiopathic Arthritis (JIA), Localized Scleroderma, Arthritis, and Juvenile Dermatomyositis.
Summary: Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
Summary: The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).


